


ABSTRACT

Disclosed are compounds of the Formula I



wherein:

5 R^a , R^b , and R^c are the same or different and represent hydrogen,
(C_1 - C_6)-alkyl, (C_2 - C_6)-alkenyl, unsubstituted aryl, unsubstituted
heteroaryl, unsubstituted arylalkyl, or unsubstituted
heteroarylalkyl;

10 R^1 and R^2 are the same or different and represent hydrogen,
(C_1 - C_6)-alkyl, (C_2 - C_6)-alkenyl, unsubstituted aryl, unsubstituted
heteroaryl, unsubstituted arylalkyl, or unsubstituted
heteroarylalkyl;

15 n is 0, 2, or 3, provided that when the imidazole is attached at the
imidazole nitrogen to $(CR^aR^b)_n$ and Y is O, NR^c , or S, then n is
not 0;

Y is NR^c , O, $-CHR^c$, or S; and

R^3 is unsubstituted aryl, unsubstituted heteroarylalkyl or unsubstituted
arylalkyl.

20 The present invention also provides a pharmaceutically acceptable
composition that comprises a compound of Formula I.

25 The present invention also provides a method of treating or
preventing restenosis, atherosclerosis or cancer, the method comprising
administering to a patient having restenosis, atherosclerosis or cancer, or at
risk of having restenosis, atherosclerosis or cancer, a therapeutically
effective amount of Formula I.

Also provided is a method of treating or preventing restenosis or atherosclerosis, or treating cancer, the method of comprising administering to a patient having restenosis or atherosclerosis, or at risk of having restenosis or atherosclerosis, or having cancer a therapeutically effective amount of a compound of Formula I.